T. Rowe Price Associates
ALGS icon

T. Rowe Price Associates’s Aligos Therapeutics ALGS Stock Holding History

T. Rowe Price Associates’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-903
Closed -$49K – 2959
2022
Q1 		$49K Buy
903
+20
+2% +$1.6K ﹤0.01% 2923
2021
Q4 		$262K Sell
883
-208
-19% -$75.9K ﹤0.01% 2653
2021
Q3 		$423K Buy
1,091
+2
+0.2% +$791 ﹤0.01% 2450
2021
Q2 		$555K Buy
+1,089
New +$694K ﹤0.01% 2341

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's ALGS Position: Q2 2022 in Review

T. Rowe Price Associates sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 903 shares — an estimated $49K sold.

T. Rowe Price Associates first reported a position in ALGS in Q2 2021 and held it in 4 quarters. The position peaked at $555K in Q2 2021. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

  • T. Rowe Price Associates reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 903 Aligos Therapeutics shares in Q2 2022, an estimated $49K.
  • T. Rowe Price Associates first reported a position in Aligos Therapeutics in Q2 2021 and held it in 4 quarters.
  • T. Rowe Price Associates's Aligos Therapeutics position peaked at $555K in Q2 2021.
  • 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.